Marianne Jertborn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marianne Jertborn has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Ann-Mari Svennerholm
Department of Medical Microbiology and Immunology,1 Department of Infectious Diseases,2 and Department of Surgery,3 Sahlgrenska University Hospital, Göteborg University, Göteborg, Sweden
3 shared publicationsHans Brevinge
Department of Medical Microbiology and Immunology,1 Department of Infectious Diseases,2 and Department of Surgery,3 Sahlgrenska University Hospital, Göteborg University, Göteborg, Sweden
2 shared publications- Jan Holmgren
Department of Microbiology and Immunology, University of Gothenburg, 40530 Gothenburg, Sweden
2 shared publications Jan Kilhamn
Department of Medical Microbiology and Immunology, Sahlgrenska University Hospital, Göteborg University, Göteborg, Sweden
2 shared publicationsAnders Kilander
Department of Medical Microbiology and Immunology,1 Department of Infectious Diseases,2 and Institute of Internal Medicine, Department of Gastroenterology,3 Sahlgrenska University Hospital, Göteborg, Sweden
1 shared publication- Ann-Mari Svennerholm
University of Gothenburg Vaccine Research Institute (GUVAX), Dept. of Microbiology and Immunology, University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden
1 shared publication
Latest Publications
- 1 June 2001
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 69 (6) , 4125-4128
Local and Systemic Immune Responses to Rectal Administration of Recombinant Cholera Toxin B Subunit in Humans
The induction of immune responses to rectally administered recombinant cholera toxin B subunit (CTB) in humans was studied. Three immunizations induced high levels of CTB-specific antibody-secreting cells, particular of the immunoglobulin A isotype, in both rectum and peripheral blood. Antitoxin antibody responses in rectal secretions and serum were also found.
- 1 June 2001
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 69 (6) , 4125-4128
Local and Systemic Immune Responses to Rectal Administration of Recombinant Cholera Toxin B Subunit in Humans
The induction of immune responses to rectally administered recombinant cholera toxin B subunit (CTB) in humans was studied. Three immunizations induced high levels of CTB-specific antibody-secreting cells, particular of the immunoglobulin A isotype, in both rectum and peripheral blood. Antitoxin antibody responses in rectal secretions and serum were also found.
- Open Access
- 1 May 2001
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 69 (5) , 3466-3471
Induction and Distribution of Intestinal Immune Responses after Administration of Recombinant Cholera Toxin B Subunit in the Ileal Pouches of Colectomized Patients
The induction and dissemination of mucosal immune responses to recombinant cholera toxin B subunit (rCTB) administered into the ileal pouches of patients, who had been colectomized because of ulcerative colitis, was analyzed. Biopsies from the duodenum and ileal pouch were collected, along with peripheral blood and ileostomy fluids. Two immunizations induced strong CTB-specific immunoglobulin A (IgA) antibody-secreting cell (ASC) responses in the duodenum in five of five patients, whereas weaker and less-frequent ASC responses were noted in the ileal pouch. Intestine-derived CTB-specific IgA ASCs were found in peripheral blood in three of the five patients. The vaccination also induced significant IgA antitoxin titer rises in ileostomy fluid in all of the patients. Increased production of gamma interferon in cell cultures from the ileal pouch was found in four of five patients after the vaccination. These results clearly indicate that rCTB administered into the distal ileum is capable of inducing B-cell responses in the “entire” small intestine and that homing of immunocompetent cells occurs preferentially to the duodenum.
- 1 May 2001
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 69 (5) , 3466-3471
Open AccessInduction and Distribution of Intestinal Immune Responses after Administration of Recombinant Cholera Toxin B Subunit in the Ileal Pouches of Colectomized Patients
The induction and dissemination of mucosal immune responses to recombinant cholera toxin B subunit (rCTB) administered into the ileal pouches of patients, who had been colectomized because of ulcerative colitis, was analyzed. Biopsies from the duodenum and ileal pouch were collected, along with peripheral blood and ileostomy fluids. Two immunizations induced strong CTB-specific immunoglobulin A (IgA) antibody-secreting cell (ASC) responses in the duodenum in five of five patients, whereas weaker and less-frequent ASC responses were noted in the ileal pouch. Intestine-derived CTB-specific IgA ASCs were found in peripheral blood in three of the five patients. The vaccination also induced significant IgA antitoxin titer rises in ileostomy fluid in all of the patients. Increased production of gamma interferon in cell cultures from the ileal pouch was found in four of five patients after the vaccination. These results clearly indicate that rCTB administered into the distal ileum is capable of inducing B-cell responses in the “entire” small intestine and that homing of immunocompetent cells occurs preferentially to the duodenum.
- 1 March 2001
- Published by American Society for Microbiology in Clinical and Diagnostic Laboratory Immunology
- Vol. 8 (2) , 424-8
Dose-Dependent Circulating Immunoglobulin A Antibody-Secreting Cell and Serum Antibody Responses in Swedish Volunteers to an Oral Inactivated Enterotoxigenic Escherichia coli Vaccine
The immunogenicity of different preparations of an oral inactivated enterotoxigenic Escherichia coli (ETEC) vaccine was evaluated in Swedish volunteers previously unexposed to ETEC infection. The vaccine preparations consisted of recombinant cholera toxin B subunit (CTB) and various amounts of formalin-killed whole bacteria expressing the most prevalent colonization factor antigens (CFAs). Significant immunoglobulin A (IgA) antibody-secreting cell (ASC) responses against CTB and the various CFA components were seen in a majority of volunteers after two doses of ETEC vaccine independent of the vaccine lot given. The IgA ASC responses against CTB were significantly higher after the second than after the first immunization, whereas the CFA-specific IgA ASC responses were almost comparable after the first and second doses of ETEC vaccine. Two immunizations with one-third of a full dose of CFA-ETEC bacteria induced lower frequencies of IgA ASC responses against all the different CFAs than two full vaccine doses, i.e., 63 versus 80% for CFA/I, 56 versus 70% for CS1, 31 versus 65% for CS2, and 56 versus 75% for CS4. The proportion of vaccinees responding with rises in the titer of serum IgA antibody against the various CFA antigens was also lower after immunization with the reduced dose of CFA-ETEC bacteria. These findings suggest that measurements of circulating IgA ASCs can be used not only for qualitative but also for quantitative assessments of the immunogenicity of individual fimbrial antigens in various preparations of ETEC vaccine.
- 1 March 2001
- Published by American Society for Microbiology in Clinical and Diagnostic Laboratory Immunology
- Vol. 8 (2) , 424-8
Dose-Dependent Circulating Immunoglobulin A Antibody-Secreting Cell and Serum Antibody Responses in Swedish Volunteers to an Oral Inactivated Enterotoxigenic Escherichia coli Vaccine
The immunogenicity of different preparations of an oral inactivated enterotoxigenic Escherichia coli (ETEC) vaccine was evaluated in Swedish volunteers previously unexposed to ETEC infection. The vaccine preparations consisted of recombinant cholera toxin B subunit (CTB) and various amounts of formalin-killed whole bacteria expressing the most prevalent colonization factor antigens (CFAs). Significant immunoglobulin A (IgA) antibody-secreting cell (ASC) responses against CTB and the various CFA components were seen in a majority of volunteers after two doses of ETEC vaccine independent of the vaccine lot given. The IgA ASC responses against CTB were significantly higher after the second than after the first immunization, whereas the CFA-specific IgA ASC responses were almost comparable after the first and second doses of ETEC vaccine. Two immunizations with one-third of a full dose of CFA-ETEC bacteria induced lower frequencies of IgA ASC responses against all the different CFAs than two full vaccine doses, i.e., 63 versus 80% for CFA/I, 56 versus 70% for CS1, 31 versus 65% for CS2, and 56 versus 75% for CS4. The proportion of vaccinees responding with rises in the titer of serum IgA antibody against the various CFA antigens was also lower after immunization with the reduced dose of CFA-ETEC bacteria. These findings suggest that measurements of circulating IgA ASCs can be used not only for qualitative but also for quantitative assessments of the immunogenicity of individual fimbrial antigens in various preparations of ETEC vaccine.
- 1 October 2000
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 68 (10) , 6077-6081
Enterotoxin-Specific Immunoglobulin E Responses in Humans after Infection or Vaccination with Diarrhea-Causing Enteropathogens
Cholera toxin (CT)-specific antibody responses of the immunoglobulin E (IgE) isotype in the sera of adult patients suffering from infection with eitherVibrio choleraeO1,V. choleraeO139, or enterotoxigenicEscherichia coli(ETEC) were analyzed and compared with those in the sera of volunteers immunized with a bivalent B subunit O1/O139 whole-cell cholera vaccine. A significant IgE response to CT was observed in 90% of the patients withV. choleraeO1 infection (18 of 20;P= V. choleraeO139 infection (19 of 20;P= V. choleraeO1 showed CT-specific IgE responses (P= 0.004). In contrast, Swedish volunteers immunized with the oral cholera vaccine showed no IgE responses to CT (Pvalue not significant). During the study period, total IgE levels in the sera of the diarrheal patients, the North American volunteers, and the Swedish cholera vaccinees alike remained unchanged. However, the total IgE levels in the sera of patients and healthy Bangladeshi controls were on average 89-fold higher than those in the sera of the healthy Swedish volunteers and 34-fold higher than those in the sera of the North American volunteers.
- 1 October 2000
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 68 (10) , 6077-6081
Enterotoxin-Specific Immunoglobulin E Responses in Humans after Infection or Vaccination with Diarrhea-Causing Enteropathogens
Cholera toxin (CT)-specific antibody responses of the immunoglobulin E (IgE) isotype in the sera of adult patients suffering from infection with eitherVibrio choleraeO1,V. choleraeO139, or enterotoxigenicEscherichia coli(ETEC) were analyzed and compared with those in the sera of volunteers immunized with a bivalent B subunit O1/O139 whole-cell cholera vaccine. A significant IgE response to CT was observed in 90% of the patients withV. choleraeO1 infection (18 of 20;P= V. choleraeO139 infection (19 of 20;P= V. choleraeO1 showed CT-specific IgE responses (P= 0.004). In contrast, Swedish volunteers immunized with the oral cholera vaccine showed no IgE responses to CT (Pvalue not significant). During the study period, total IgE levels in the sera of the diarrheal patients, the North American volunteers, and the Swedish cholera vaccinees alike remained unchanged. However, the total IgE levels in the sera of patients and healthy Bangladeshi controls were on average 89-fold higher than those in the sera of the healthy Swedish volunteers and 34-fold higher than those in the sera of the North American volunteers.
- 1 August 1998
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 66 (8) , 3995-9
Immune Responses in Ileostomy Fluid and Serum after Oral Cholera Vaccination of Patients Colectomized because of Ulcerative Colitis
The capacity of an oral inactivated B-subunit–whole-cell cholera vaccine to induce immune responses in patients colectomized due to ulcerative colitis was studied. Two doses of vaccine induced significant mucosal immunoglobulin A (IgA) antibody responses in ileostomy fluid against cholera toxin in 14 of 15 (93%) patients and against whole vibrios in 9 of 15 (60%) cases. The serological responses were lower (but not significantly) than those observed in healthy Swedish volunteers. Increased IgA antitoxin levels were found in ileostomy fluid as late as 2 years after vaccination.
- 1 August 1998
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 66 (8) , 3995-9
Immune Responses in Ileostomy Fluid and Serum after Oral Cholera Vaccination of Patients Colectomized because of Ulcerative Colitis
The capacity of an oral inactivated B-subunit–whole-cell cholera vaccine to induce immune responses in patients colectomized due to ulcerative colitis was studied. Two doses of vaccine induced significant mucosal immunoglobulin A (IgA) antibody responses in ileostomy fluid against cholera toxin in 14 of 15 (93%) patients and against whole vibrios in 9 of 15 (60%) cases. The serological responses were lower (but not significantly) than those observed in healthy Swedish volunteers. Increased IgA antitoxin levels were found in ileostomy fluid as late as 2 years after vaccination.